Intellia Therapeutics has reached a pivotal milestone in the field of genetic medicine, announcing that its CRISPR-based therapy for hereditary angioedema (HAE) has successfully met all primary endpoints in a Phase 3 clinical trial. The treatment, known as lonvoguran ziclumeran, utilizes in vivo gene editing to directly modify DNA within the liver, effectively silencing the […]